EPCA-2

The common choices for screening prostate cancer are the digital rectal exam and the prostate specific antigen (PSA) blood test. Last year, another method of screening prostate cancer has been tested. It’s called the early prostate cancer antigen 2 or EPCA-2. It is another method of blood testing and said to be able to determine the spreading of the cancer and said to be better than PSA with regard to this aspect.

According to Robert H. Getzenberg, PhD, director of urology research at Johns Hopkins University’s Brady Urological Institute the test has 3% margin of error. This means that if the test shows that the patient has prostate cancer, it is 97% accurate. Once this method is approved, it is expected that this will replace other existing tests and shall be widely used.